Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy

Roberto Puzone, Laura Paleari, Franco Montefiore, Luca Ruggiero, Matteo Puntoni, Massimo Maffezzini, Barbara Bobbio, Paola Marroni, Roberta Libener, Pier Giacomo Betta

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Prostate cancer is the second most frequent cause of tumor-related deaths in men in Western countries. The selection and evaluation of new markers might help to overcome the limits of the most widely used diagnostic tool, the prostate-specific antigen (PSA) test, often combined with digital rectal examination (DRE). Osteopontin (OPN) is an integrin-binding glycoprotein that has recently been shown to be related to tumor development, progression and metastasis in both experimental and clinical studies. The present study compares plasma OPN levels and tumor presence and grade in a group of PSA/DRE-positive patients referred for diagnostic prostate biopsy. Methods: Plasma OPN levels were measured by enzyme-linked immunosorbent assay in blood samples of 194 PSA/DRE-positive patients referred for diagnostic prostate biopsy. OPN measurements were compared with PSA levels and tumor presence and grade as established by needle biopsy. Results: Plasma OPN levels were not increased in patients with prostate cancer, and in patients with high-grade prostate cancer the plasma OPN levels were not different from those in patients with low-grade or no prostate cancer. Conclusions: In PSA/DRE-positive patients referred for diagnostic prostate biopsy, OPN does not appear to be a plasma marker able to detect prostate cancer or high-grade prostate cancer.

Original languageEnglish
Pages (from-to)200-206
Number of pages7
JournalInternational Journal of Biological Markers
Volume25
Issue number4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Osteopontin
Biopsy
Prostate
Prostatic Neoplasms
Prostate-Specific Antigen
Digital Rectal Examination
Plasmas
Tumors
Neoplasms
Immunosorbents
Needle Biopsy
Integrins
Needles
Assays
Glycoproteins
Blood
Enzyme-Linked Immunosorbent Assay
Neoplasm Metastasis
Enzymes

Keywords

  • Circulating tumor markers
  • Osteopontin
  • Prostate cancer
  • PSA

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy. / Puzone, Roberto; Paleari, Laura; Montefiore, Franco; Ruggiero, Luca; Puntoni, Matteo; Maffezzini, Massimo; Bobbio, Barbara; Marroni, Paola; Libener, Roberta; Betta, Pier Giacomo.

In: International Journal of Biological Markers, Vol. 25, No. 4, 10.2010, p. 200-206.

Research output: Contribution to journalArticle

Puzone, R, Paleari, L, Montefiore, F, Ruggiero, L, Puntoni, M, Maffezzini, M, Bobbio, B, Marroni, P, Libener, R & Betta, PG 2010, 'Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy', International Journal of Biological Markers, vol. 25, no. 4, pp. 200-206. https://doi.org/10.5301/JBM.2010.6116
Puzone, Roberto ; Paleari, Laura ; Montefiore, Franco ; Ruggiero, Luca ; Puntoni, Matteo ; Maffezzini, Massimo ; Bobbio, Barbara ; Marroni, Paola ; Libener, Roberta ; Betta, Pier Giacomo. / Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy. In: International Journal of Biological Markers. 2010 ; Vol. 25, No. 4. pp. 200-206.
@article{72721148204a4c83bebeb03dd9210771,
title = "Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy",
abstract = "Background: Prostate cancer is the second most frequent cause of tumor-related deaths in men in Western countries. The selection and evaluation of new markers might help to overcome the limits of the most widely used diagnostic tool, the prostate-specific antigen (PSA) test, often combined with digital rectal examination (DRE). Osteopontin (OPN) is an integrin-binding glycoprotein that has recently been shown to be related to tumor development, progression and metastasis in both experimental and clinical studies. The present study compares plasma OPN levels and tumor presence and grade in a group of PSA/DRE-positive patients referred for diagnostic prostate biopsy. Methods: Plasma OPN levels were measured by enzyme-linked immunosorbent assay in blood samples of 194 PSA/DRE-positive patients referred for diagnostic prostate biopsy. OPN measurements were compared with PSA levels and tumor presence and grade as established by needle biopsy. Results: Plasma OPN levels were not increased in patients with prostate cancer, and in patients with high-grade prostate cancer the plasma OPN levels were not different from those in patients with low-grade or no prostate cancer. Conclusions: In PSA/DRE-positive patients referred for diagnostic prostate biopsy, OPN does not appear to be a plasma marker able to detect prostate cancer or high-grade prostate cancer.",
keywords = "Circulating tumor markers, Osteopontin, Prostate cancer, PSA",
author = "Roberto Puzone and Laura Paleari and Franco Montefiore and Luca Ruggiero and Matteo Puntoni and Massimo Maffezzini and Barbara Bobbio and Paola Marroni and Roberta Libener and Betta, {Pier Giacomo}",
year = "2010",
month = "10",
doi = "10.5301/JBM.2010.6116",
language = "English",
volume = "25",
pages = "200--206",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Osteopontin plasma level does not detect prostate cancer in patients referred for diagnostic prostate biopsy

AU - Puzone, Roberto

AU - Paleari, Laura

AU - Montefiore, Franco

AU - Ruggiero, Luca

AU - Puntoni, Matteo

AU - Maffezzini, Massimo

AU - Bobbio, Barbara

AU - Marroni, Paola

AU - Libener, Roberta

AU - Betta, Pier Giacomo

PY - 2010/10

Y1 - 2010/10

N2 - Background: Prostate cancer is the second most frequent cause of tumor-related deaths in men in Western countries. The selection and evaluation of new markers might help to overcome the limits of the most widely used diagnostic tool, the prostate-specific antigen (PSA) test, often combined with digital rectal examination (DRE). Osteopontin (OPN) is an integrin-binding glycoprotein that has recently been shown to be related to tumor development, progression and metastasis in both experimental and clinical studies. The present study compares plasma OPN levels and tumor presence and grade in a group of PSA/DRE-positive patients referred for diagnostic prostate biopsy. Methods: Plasma OPN levels were measured by enzyme-linked immunosorbent assay in blood samples of 194 PSA/DRE-positive patients referred for diagnostic prostate biopsy. OPN measurements were compared with PSA levels and tumor presence and grade as established by needle biopsy. Results: Plasma OPN levels were not increased in patients with prostate cancer, and in patients with high-grade prostate cancer the plasma OPN levels were not different from those in patients with low-grade or no prostate cancer. Conclusions: In PSA/DRE-positive patients referred for diagnostic prostate biopsy, OPN does not appear to be a plasma marker able to detect prostate cancer or high-grade prostate cancer.

AB - Background: Prostate cancer is the second most frequent cause of tumor-related deaths in men in Western countries. The selection and evaluation of new markers might help to overcome the limits of the most widely used diagnostic tool, the prostate-specific antigen (PSA) test, often combined with digital rectal examination (DRE). Osteopontin (OPN) is an integrin-binding glycoprotein that has recently been shown to be related to tumor development, progression and metastasis in both experimental and clinical studies. The present study compares plasma OPN levels and tumor presence and grade in a group of PSA/DRE-positive patients referred for diagnostic prostate biopsy. Methods: Plasma OPN levels were measured by enzyme-linked immunosorbent assay in blood samples of 194 PSA/DRE-positive patients referred for diagnostic prostate biopsy. OPN measurements were compared with PSA levels and tumor presence and grade as established by needle biopsy. Results: Plasma OPN levels were not increased in patients with prostate cancer, and in patients with high-grade prostate cancer the plasma OPN levels were not different from those in patients with low-grade or no prostate cancer. Conclusions: In PSA/DRE-positive patients referred for diagnostic prostate biopsy, OPN does not appear to be a plasma marker able to detect prostate cancer or high-grade prostate cancer.

KW - Circulating tumor markers

KW - Osteopontin

KW - Prostate cancer

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=78650846774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650846774&partnerID=8YFLogxK

U2 - 10.5301/JBM.2010.6116

DO - 10.5301/JBM.2010.6116

M3 - Article

VL - 25

SP - 200

EP - 206

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -